Astellas joins forces with Ambrx to develop antibody-drug conjugates

04/8/2013 | Genetic Engineering & Biotechnology News

Astellas Pharma and Ambrx agreed to collaborate in the discovery and development of antibody-drug conjugates for cancer using the latter's site-specific conjugation technology, linkers and drug payloads. Ambrx will get $15 million upfront plus as much as $285 million in milestone fees and sales royalties. The rights to further develop and market the ADCs will go to Astellas.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR CLINICAL RESEARCH - 14000003MB
Abbott
Santa Clara, CA
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC
Chief Financial Officer
B. E. Smith
Miramar, FL
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA